WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H333104
CAS#: 51-48-9 (free)
Description: Levothyroxine, also known as L-Thyroxine, is a synthetic form of the thyroid hormone thyroxine (T4). It is used to treat thyroid hormone deficiency (hypothyroidism), including a severe form known as myxedema coma.[4] It may also be used to treat and prevent certain types of thyroid tumors. T4 is a prohormone, i.e., it is a precursor to the hormone T3. Whereas T4 is a tetraiodide, T3 is a triiodide, triiodothyronine. The T4 → T3 conversion is mediated by the selenoenzyme iodothyronine deiodinase. T3-thyroxine it is a unique example of an iodine compound that is essential for human health. T3 bind to thyroid receptor proteins in the cell nucleus and cause metabolic effects through the control of DNA transcription and protein synthesis.
Hodoodo Cat#: H333104
Name: Levothyroxine
CAS#: 51-48-9 (free)
Chemical Formula: C15H11I4NO4
Exact Mass: 776.69
Molecular Weight: 776.874
Elemental Analysis: C, 23.19; H, 1.43; I, 65.34; N, 1.80; O, 8.24
Related CAS #: 51-48-9 (free) 55-03-8 (sodium) 6106-07-6 (sodium pentahydrate) 25416-65-3 (sodium hydrate)
Synonym: L-T4; L-Thyroxin; Henning; Levothyroxine; Levotiron; MeSH ID: D013974; NSC 36397; SK&F 1-6528; T4; T4 (hormone); Tetraiodothyronine; THX; Thyrax; Thyreoideum; Thyroxin; Thyroxinal; Thyroxine;
IUPAC/Chemical Name: L-Tyrosine, O-(4-hydroxy-3,5-diiodophenyl)-3,5-diiodo-
InChi Key: XUIIKFGFIJCVMT-LBPRGKRZSA-N
InChi Code: InChI=1S/C15H11I4NO4/c16-8-4-7(5-9(17)13(8)21)24-14-10(18)1-6(2-11(14)19)3-12(20)15(22)23/h1-2,4-5,12,21H,3,20H2,(H,22,23)/t12-/m0/s1
SMILES Code: N[C@@H](CC1=CC(I)=C(OC2=CC(I)=C(O)C(I)=C2)C(I)=C1)C(O)=O
Appearance: Solid powder
Purity: >97% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: To be determined
Shelf Life: >2 years if stored properly
Drug Formulation: To be determined
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
| Biological target: | |
| In vitro activity: | |
| In vivo activity: |
The following data is based on the product molecular weight 776.87 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | |
| In vitro protocol: | |
| In vivo protocol: |
1: Metry M, Yusuf ARS, Lane J, Unwala R, Altisheh R. Urticarial Vasculitis Associated With Levothyroxine. Cureus. 2023 Jun 21;15(6):e40754. doi: 10.7759/cureus.40754. PMID: 37485155; PMCID: PMC10361698.
2: Alofi RM, Alrohaily LS, Jan RA, Alsaedi SL, Mahrous FA, Alreefi MM. Adherence to Levothyroxine Treatment Among Patients With Hypothyroidism in Madinah, Saudi Arabia: A Cross-Sectional Study. Cureus. 2023 Jun 20;15(6):e40686. doi: 10.7759/cureus.40686. PMID: 37485132; PMCID: PMC10358293.
3: Duntas LH. Focusing on the critical role of age and sex in the diagnosis of subclinical hypothyroidism and associated levothyroxine prescription. Thyroid. 2023 Jul 20. doi: 10.1089/thy.2023.0340. Epub ahead of print. PMID: 37470221.
4: Zhao Z, Zhou Q, Zhao H, Xiong Y, Li X. Association between levothyroxine treatment for maternal subclinical hypothyroidism with negative TPOAb and early child neurodevelopment: A prospective real-world clinical trial. Acta Obstet Gynecol Scand. 2023 Jul 13. doi: 10.1111/aogs.14602. Epub ahead of print. PMID: 37443452.
5: Yu M, Long Y, Wang Y, Zhang R, Tao L. Effect of levothyroxine on the pregnancy outcomes in recurrent pregnancy loss women with subclinical hypothyroidism and thyroperoxidase antibody positivity: a systematic review and meta-analysis. J Matern Fetal Neonatal Med. 2023 Dec;36(2):2233039. doi: 10.1080/14767058.2023.2233039. PMID: 37433649.
6: Casula S, Ettleson MD, Bianco AC. Are We Restoring Thyroid Hormone Signaling in Levothyroxine-Treated Patients With Residual Symptoms of Hypothyroidism? Endocr Pract. 2023 Jul;29(7):581-588. doi: 10.1016/j.eprac.2023.04.003. PMID: 37419565.
7: Hennessey JV. Levothyroxine Monotherapy: What Works Better for the Individual With Hypothyroidism? Endocr Pract. 2023 Jul;29(7):572-580. doi: 10.1016/j.eprac.2022.12.013. PMID: 37419564.
8: Rahman FB, Zubery MH, Moni SY, Ara S, Sultana Z, Islam MN. Impact of Levothyroxine on Lipid Profile in Patients with Hypothyroidism. Mymensingh Med J. 2023 Jul;32(3):727-731. PMID: 37391966.
9: Gavigan C, Abbey EJ, McGready J, Simonsick EM, Mammen JS. Levothyroxine Dosing in Older Adults: Recommendations Derived From The Baltimore Longitudinal Study of Aging. Endocr Pract. 2023 Jun 28:S1530-891X(23)00404-4. doi: 10.1016/j.eprac.2023.05.002. Epub ahead of print. PMID: 37391043.
10: Liu H, Lu M, Hu J, Fu G, Feng Q, Sun S, Chen C. Medications and Food Interfering with the Bioavailability of Levothyroxine: A Systematic Review. Ther Clin Risk Manag. 2023 Jun 23;19:503-523. doi: 10.2147/TCRM.S414460. PMID: 37384019; PMCID: PMC10295503.
11: Sharma R, Theiler-Schwetz V, Trummer C, Pilz S, Reichhartinger M. Automatic Levothyroxine Dosing Algorithm for Patients Suffering from Hashimoto's Thyroiditis. Bioengineering (Basel). 2023 Jun 14;10(6):724. doi: 10.3390/bioengineering10060724. PMID: 37370655; PMCID: PMC10294790.
12: Benabdelkamel H, Jaber MA, Dahabiyeh LA, Masood A, Almalki RH, Musambil M, Abdel Rahman AM, Alfadda AA. Metabolomic profile of patients on levothyroxine treatment for hypothyroidism. Eur Thyroid J. 2023 Jul 27;12(4):e230062. doi: 10.1530/ETJ-23-0062. PMID: 37343156; PMCID: PMC10388654.
13: Bianco AC, Bao Y, Antunez Flores O, Halpern R, Le L, Stackland S, Frieze T. Levothyroxine Treatment Adequacy and Formulation Changes in Patients with Hypothyroidism: A Retrospective Study of Real-World Data from the United States. Thyroid. 2023 Jul 6. doi: 10.1089/thy.2022.0382. Epub ahead of print. PMID: 37335236.
14: Dempsey AL, Wang GH, Singh Ospina N, Vouri SM. Concomitant use of levothyroxine and interacting medications in U.S. ambulatory care visits. J Am Pharm Assoc (2003). 2023 Jun 15:S1544-3191(23)00192-9. doi: 10.1016/j.japh.2023.06.008. Epub ahead of print. PMID: 37329957.
15: Uzun ME, Kaymaz N, Kara O, Kasap T. Are Mental Health Problems and Mindfulness Awareness Related to Levothyroxine Replacement in Adolescent Patients With Hashimoto's Thyroiditis? Clin Pediatr (Phila). 2023 Jun 14:99228231180398. doi: 10.1177/00099228231180398. Epub ahead of print. PMID: 37313800.
16: Yamamoto M, Miyauchi A, Ito Y, Fujishima M, Sasaki T, Kudo T. Active Surveillance Outcomes of Patients with Low-Risk Papillary Thyroid Microcarcinoma According to Levothyroxine Treatment Status. Thyroid. 2023 Jul 5. doi: 10.1089/thy.2023.0046. Epub ahead of print. PMID: 37310904.
17: Csiha S, Molnár I, Halmi S, Hutkai D, Lőrincz H, Somodi S, Katkó M, Harangi M, Paragh G, Nagy EV, Berta E, Bodor M. Advanced glycation end products and their soluble receptor (sRAGE) in patients with Hashimoto's thyroiditis on levothyroxine substitution. Front Endocrinol (Lausanne). 2023 May 26;14:1187725. doi: 10.3389/fendo.2023.1187725. PMID: 37305044; PMCID: PMC10250717.
18: Alfaifi HH, Altowairgi MA, Algethami RG, Altowairqi AH, Althomali HD, Almalki OM. Effectiveness of Bariatric Surgery for Improving Thyroid Function and Reducing Levothyroxine Dose in Patients With Obesity and Overt Hypothyroidism. Cureus. 2023 May 9;15(5):e38780. doi: 10.7759/cureus.38780. PMID: 37303346; PMCID: PMC10249914.
19: Caron P. Key data from the 2022 European Thyroid Association congress: Treatment of primary hypothyroidism: Levothyroxine alone or a combination of levothyroxine and liothyronine? Ann Endocrinol (Paris). 2023 Jun 5:S0003-4266(23)00108-7. doi: 10.1016/j.ando.2023.05.005. Epub ahead of print. PMID: 37285954.
20: Awasthi A, Chakraborty PP, Agrawal N, Sinha A, Pandey AK, Maiti A. Effect of morning versus night-time administration of proton pump inhibitor (pantoprazole) on thyroid function test in levothyroxine-treated primary hypothyroidism: a prospective cross-over study. Thyroid Res. 2023 Jun 1;16(1):15. doi: 10.1186/s13044-023-00156-6. PMID: 37259094; PMCID: PMC10231962.
